MARKET

XENE

XENE

Xenon Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.79
-0.13
-0.65%
After Hours: 19.42 -0.37 -1.87% 16:00 03/08 EST
OPEN
19.90
PREV CLOSE
19.92
HIGH
20.32
LOW
19.26
VOLUME
167.16K
TURNOVER
--
52 WEEK HIGH
21.87
52 WEEK LOW
7.00
MARKET CAP
708.66M
P/E (TTM)
-22.3894
1D
5D
1M
3M
1Y
5Y
Xenon strikes research deal for major depressive disorder treatment XEN1101
Xenon Pharmaceuticals (XENE) announces collaboration with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to facilitate an investigator-sponsored Phase 2 proof-of-concept, randomized, parallel-arm, placebo-controlled clinical trial of XEN1101
Seekingalpha · 4h ago
BRIEF-Xenon Pharmaceuticals Announces Collaboration With Researchers At Icahn School Of Medicine At Mount Sinai To Conduct A Phase 2 Study Of XEN1101 For The Treatment Of Major Depressive Disorder (Mdd)
reuters.com · 4h ago
Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder
Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical stage biopharmaceutical company, today announced a collaboration with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to facilitate an investigator-sponsored
Benzinga · 5h ago
Xenon Pharmaceuticals Collaborates With Icahn School of Medicine for XEN1101 Clinical Trial in Patients With Major Depressive Disorder
MT Newswires · 8h ago
William Blair Believes Xenon (XENE) Won’t Stop Here
William Blair analyst Tim Lugo maintained a Buy rating on Xenon (XENE) on February 25. The company's shares closed last Thursday at $19.77, close to its
SmarterAnalyst · 3d ago
The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2)
Benzinga · 5d ago
DJ Xenon Pharmaceuticals Up 15% After Results, Corporate Update
Dow Jones · 6d ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XENE. Analyze the recent business situations of Xenon Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XENE stock price target is 25.29 with a high estimate of 28.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 117
Institutional Holdings: 30.90M
% Owned: 86.28%
Shares Outstanding: 35.81M
TypeInstitutionsShares
Increased
25
1.56M
New
17
-332.14K
Decreased
21
1.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Non-Executive Chairman/Independent Director
Michael Tarnow
President/Chief Financial Officer/Secretary
Ian Mortimer
Chief Executive Officer/Director
Simon Pimstone
Executive Vice President
Robin Sherrington
Senior Vice President/Director of Human Resources
Shelley McCloskey
Senior Vice President
James Empfield
Vice President - Finance
Sherry Aulin
Other
Ernesto Aycardi
Other
Ernesto Aycardi-Fonseca
Director
Patrick Machado
Independent Director
Mohammad Azab
Independent Director
Clarissa Desjardins
Independent Director
Steven Gannon
Independent Director
Michael Hayden
Independent Director
Frank Holler
Independent Director
Gary Patou
Independent Director
Dawn Svoronos
No Data
  • All
  • Financials
  • Insiders
More
About XENE
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Webull offers kinds of Xenon Pharmaceuticals Inc stock information, including NASDAQ:XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.